Nivolumab monotherapy yielded 12-month progression-free survival in metastatic anaplastic thyroid cancer

This publication is a case report and review of the literature focusing on the use of nivolumab in metastatic anaplastic thyroid cancer. The report details the experience of a single 76-year-old female patient treated with off-label immunotherapy using an immune checkpoint inhibitor. No comparator was used in this single-patient analysis. The study setting was not reported. Funding or conflicts of interest were not reported.

The patient received nivolumab monotherapy. Secondary outcomes included radiographic response, clinical response, progression-free survival, and overall survival. The patient maintained progression-free survival for 12 months and overall survival for 18 months. No specific adverse events, serious adverse events, discontinuations, or tolerability data were reported.

The authors acknowledge a key limitation: the need for clinical trials to confirm the efficacy of immunotherapy in anaplastic thyroid cancer. The authors state that ICIs may represent a valuable therapeutic option for patients with metastatic ATC exhibiting high PD-L1 expression. This conclusion is based on a single case and should be interpreted with caution.